Increasing BMI has been correlated with higher mortality risks, including a 29% rise in overall mortality and over a 200% increase in diabetes-related mortality for every 5-unit BMI increase above 25 kg/m (4)
The weight-loss- specic version, Wegovy, was approved by the US FDA in June 2021 for once-weekly 2.4 mg subcutaneous injections
However, iGlarLixi patients had more gastrointestinal-related adverse, primarily nausea (16.9% vs
L-carnitine plays a critical role in energy production, among other things, making it a valuable addition to your routine
GLP-1 side effects can look like nausea, early fullness, and changes in bowel habits, such as diarrhea or constipation, especially when starting the medication or increasing the dose
Choosing the right amount of bac water is a vital first step in your research